Navigation Links
Breast Cancer Vaccine Stimulates Potent Immune Response to Cancer Cells

Mayo Clinic researchers have designed a new strategy in the promising field of cancer vaccine research that’s proven to be successful in boosting T cells -- the immune builders akin to a super defense// force against cancer cells. Scientists say their strategy may prove to be more successful than methods currently under study and in clinical trials.

The research, which was lost to Hurricane Katrina but recovered at Mayo Clinic in Rochester, Minn., will be presented April 17 at the American Association for Cancer Research (AACR) annual meeting.

Using vaccines to prevent or slow the growth of cancerous tumors is based on the premise that the body’s immune system can be strengthened with an engineered vaccine that would stimulate an antibody and cellular response against cancer cells. Cancer vaccines are still considered experimental and so far, research results have been mixed. New studies, such as this, demonstrate that researchers are closing in on designing viable cancer vaccines, the investigators say.

In this study, Pilar Nava-Parada, M.D., Ph.D., and colleagues designed a synthetic peptide vaccine that stimulated an anti-tumor T cell response that recognized and successfully waged a battle against the spread of breast cancer cells in mouse models. (T cells are white blood cells with a key function in immune response.) Dr. Nava-Parada was a postdoctoral fellow in immunology at Mayo Clinic when she and Esteban Celis, M.D., Ph.D., began this research, which they planned to continue at Tulane University and Louisiana State University in New Orleans. But Hurricane Katrina struck before they had a chance to resume the research, so Dr. Nava-Parada returned to Mayo Clinic in Rochester where she began the research anew.

In female mouse models bred with the cancer-producing oncogene HER-2/neu, researchers administered a synthetic peptide vaccine during the early stage of tumor development. The experiment was effective in 100 p
'"/>




Page: 1 2 3 4

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Breast cancer treatment to be determined by gene test
3. Breast Feeding prevents obesity later on in life
4. Breast milk is essential
5. Breast Cancer Surgery Causes Psychological problems
6. Breast cancer evidence
7. Letrozole Beats Tamoxifen in Breast Cancer Therapy
8. Breast screening among diabetic women
9. Breast feeding can alter hormones
10. Diet, Sunlight connected to Breast Cancer Risk
11. Additional Radiotheraphy for Breast Cancer

Post Your Comments:
(Date:11/24/2009)... Developed by Opticom Data...vice for self-examination of the eye. , ...r 24, 2009 -- FloatScope is a new hand-held device...elp monitor various ocular health conditions such ...ns as well as the functioning of the iris., , , Fl...
(Date:11/23/2009)... A recent metobolomics study by researchers from V...Richmond found that impaired peroxisomal oxidation...ed with the progression of nonalcoholic fatty live... The study also found significantly higher plasma ...ts with NAFL and NASH. Full findings appear in th...
(Date:11/23/2009)... Same Day STD Testing now ...sts for all types of STD,s, including Chlamydia, H...e -- all done anonymously. , ...ing found on the web at: http://www.samedaystdtes...idential STD testing, which is now available to ac...
(Date:11/23/2009)..., ActingSecretaryEncouragesUseofPAPreferredPr...RNewswire-USNewswire/--Toensurethatyourfamilyhasas...taryRussellReddingisurgingresidentstofollowafewbas...tovers. ,, "Followingandunderstandingproperfood...akingsureyourThanksgivingdinnerissafetoeat,"saidRe...
(Date:11/23/2009)... Biomethylation of arsenic compounds appears to ca...cinogenicity, according to a new study published o...Cancer Institute . , Although biomethylation was...s now thought to enhance its toxicity and potentia...of arsenic biomethylation in oxidative DNA damage ...
Breaking Medicine News(10 mins):Health News:FloatScope - A New Device for Self-Viewing Eye Floaters 2Health News:Metobolomics uncovers key indicators of nonalcoholic fatty liver disease 2Health News:100% Anonymous, Confidential and Quick STD Screening Now Available with Same Day STD Testing 2Health News:Pennsylvania Agriculture Department Encourages Proper Food Handling, Offers Safety Tips for Thanksgiving 2
...logists, geneticists and neuroscientists has repor...ascular problems in the brain has improved spatial...Although far from proving anything about human use...t of normal aging, or even enhance learning and me...
...rocedure aids healing, experts say , , SU...umbers of baby boomers reaching retirement age, jo...more Americans. , But improved movement and lack...y faster and better. , Before going under the kn...
...,s Medical Center has been named one of the "2009...sionals magazine. , , The top 100 list acknowled... organizational levels in order to effectively ser... critical to patient care at the bedside and in th...
... 1 issue of the journal SLEEP shows that sleep d...f specific cytokines that are important in regulat...mation may be the pathway linking extreme sleep du...eactive protein (CRP) levels and a seven-percent i...
...tients Develop a Menu Game Plan , , EL SEGUNDO, C... kidney care services for those diagnosed with chr...rs kidney patients a chance to enjoy the benefits ...ging chronic kidney disease and ensuring patients,...
...ive practice plays a role, study suggests , ... regularly attend religious services may be less l...tudy suggests. , University of Manitoba researcher...ous worship and suicidal behavior. , "The main fin...
Other Medicine News:Health News:Vascular drug found to improve learning and memory in middle-aged rats 2Health News:A Checklist for Joint Replacement Surgery 2Health News:Study suggests that inflammation may be the link between extreme sleep durations and poor health 2Health News:DaVita.com Promotes Kidney-Friendly Foods for Super Bowl(R) XLIII 2Health News:DaVita.com Promotes Kidney-Friendly Foods for Super Bowl(R) XLIII 3
(Date:11/23/2009)....23/PRNewswire/--LigonDiscovery,Inc.,whichusesprop...sagainsthigh-valuetargets,todayannouncedtheappoint...sLigon,sExecutiveChairmanoftheBoard. ,, "I,mver...theBoard,"saidPatrickKleyn,Ligon,schiefexecutiveof...enceinthelifesciencesindustry--particularlyhislead...
(Date:11/23/2009)...ovalsoftwonewtherapiesforNon-Hodgkin,sLymphomas(NH...ofatumumab(Azerra(TM),GlaxoSmithKline)asatherapyop...andromidepsin(Istodax(R),GloucesterPharmaceuticals...lllymphoma(CTCL). ,, FORTWASHINGTON,Pa.,Nov.23/...romptedtheNationalComprehensiveCancerNetwork( NCCN...
(Date:11/23/2009)...wswire/--Reportlinker.comannouncesthatanewmarketre...calNonwovenDisposables-AWorldwideMarketReview ,...Nonwoven-Disposables---A-Worldwide-Market-Review.h...m_campaign=prnewswire ,, Withincreaseinrang...healthcareandhospitalfacilities,nonwovenshasemerge...
Breaking Medicine Technology:Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 2Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 4Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 5Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 6Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 7Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 8Arcadian Health Names Rick Click as New Chief Information Officer 58491 1Arcadian Health Names Rick Click as New Chief Information Officer 58491 2Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6 2009 58489 1Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 1Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 2Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 3Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 4Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 5Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 6
...x to Fund Human Clinical Trials, MINNEAPOLIS, Oct... $20 million Series B financing. Co-Founded in Jul...utonix is a medical device company,focused on the ...alloon,angioplasty technology for the treatment an...nosis caused by atherosclerosis. Lutonix,s drug co...
...es for the most common, pathogens, including meth...EINACH, Switzerland, Oct. 26 Arpida (SWX:,ARPN) t...al Phase III,clinical trials at the 48th Interscie...erapy (ICAAC)/Infectious Diseases Society of Ameri...n these studies, intravenous iclaprim, a,novel ant...
Other Medicine Technology:Lutonix Inc. Announces $20 Million Series B Financing 2Lutonix Inc. Announces $20 Million Series B Financing 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7
...Med TruFlow™ Oxygen flowmeter with a Lexan&r...nty covering calibration and manufacturing defects...meet most needs. Also available with all popular i...f and double unit configurations. Our extra large ...
...Med TruFlow™ Oxygen flowmeter with a Lexan&r...nty covering calibration and manufacturing defects...meet most needs. Also available with all popular i...f and double unit configurations. Our extra large ...
...Med TruFlow™ Oxygen flowmeter with a Lexan&r...nty covering calibration and manufacturing defects...meet most needs. Also available with all popular i...f and double unit configurations. Our extra large ...
...ates to adults, the entire series of time-tested T...surpassed knowledge of the needs of care providers...y. You can see it in the craftsmanship. You can se...meter® Classic Flowmeter is hand-crafted and e...
Medicine Products: